{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:32:45Z","timestamp":1759969965640,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Diagn\u00f3sticos da Am\u00e9rica"},{"name":"N\u00facleo de Apoio a Pesquisa, Biobanco USP, Rede Acad\u00eamica de Pesquisa em C\u00e2ncer"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.maturitas.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,6,4]],"date-time":"2017-06-04T11:16:43Z","timestamp":1496575003000},"page":"113-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Predictability of BRCA1\/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries"],"prefix":"10.1016","volume":"105","author":[{"given":"Natalia","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Maistro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Del Pilar Estevez Diz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian J.","family":"Mourits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan C.","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Aparecida Koike","family":"Folgueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertruida H.","family":"de Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2017.06.002_bib0005","unstructured":"MS\/INCA\/Estimativa de C\u00e2ncer no Brasil, 2016. Available at: http:\/\/www.inca.gov.br\/wcm\/dncc\/2015\/por-sexo.asp. Accessed 17 December 2015."},{"issue":"2","key":"10.1016\/j.maturitas.2017.06.002_bib0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12325-016-0281-1","article-title":"Selecting patients with ovarian cancer for germline BRCA mutation testing: findings from guidelines and a systematic literature review","volume":"33","author":"Eccles","year":"2016","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.maturitas.2017.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.maturitas.2017.06.002_bib0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","article-title":"Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age","volume":"124","author":"van der Kolk","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.maturitas.2017.06.002_bib0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/107327481101800103","article-title":"Screening for ovarian cancer","volume":"8","author":"Cragun","year":"2011","journal-title":"Cancer Control"},{"issue":"1","key":"10.1016\/j.maturitas.2017.06.002_bib0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2012.07.021","article-title":"Support of the \u2018fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens","volume":"49","author":"Reitsma","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.maturitas.2017.06.002_bib0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"S1","key":"10.1016\/j.maturitas.2017.06.002_bib0040","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/bjc.2015.395","article-title":"PARP inhibitors in ovarian cancer: clinical evidence for informed treatment decisions","volume":"113","author":"Ledermann","year":"2015","journal-title":"Br. J. Cancer"},{"year":"2015","series-title":"Guidelines Version 2.2015 Genetic\/Familial High Risk Assessment: Breast and Ovarian","author":"NCCN","key":"10.1016\/j.maturitas.2017.06.002_bib0045"},{"issue":"1","key":"10.1016\/j.maturitas.2017.06.002_bib0050","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1186\/s12885-016-2966-x","article-title":"Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil","volume":"16","author":"Maistro","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.maturitas.2017.06.002_bib0055","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","article-title":"The BOADICEA model of genetic susceptibility to breast and ovarian cancer","volume":"91","author":"Antoniou","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.maturitas.2017.06.002_bib0060","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","article-title":"Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals","volume":"20","author":"Frank","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2017.06.002_bib0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/301670","article-title":"Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2","volume":"2","author":"Parmigiani","year":"1998","journal-title":"Am. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.maturitas.2017.06.002_bib0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/jmg.2003.017996","article-title":"A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO","volume":"41","author":"Evans","year":"2004","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.maturitas.2017.06.002_bib0075","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1590\/1806-9282.61.03.234","article-title":"Association of family risk and lifestyle\/comorbidities in ovarian cancer patients","volume":"61","author":"Teixeira","year":"2015","journal-title":"Rev. Assoc. Med. Bras."},{"key":"10.1016\/j.maturitas.2017.06.002_bib0080","unstructured":"\u00a9 2013 Centre for Cancer Genetic Epidemiology. BOADICEA risk estimation. Available at: https:\/\/pluto.srl.cam.ac.uk\/cgi-bin\/bd3\/v3\/bd.cgi. Accessed January, 2016."},{"key":"10.1016\/j.maturitas.2017.06.002_bib0085","unstructured":"K. Hughes Hughes, Risk Apps Express Entry. Available at: http:\/\/66.118.159.147\/HRAExpressEntry\/(S(ydr4eggiiob13dr041n54qdc))\/default.aspx. Accessed April, 2016."},{"issue":"3","key":"10.1016\/j.maturitas.2017.06.002_bib0090","first-page":"441","article-title":"The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective, Breast Cancer Res","volume":"154","author":"Dutil","year":"2015","journal-title":"Treat"},{"issue":"7","key":"10.1016\/j.maturitas.2017.06.002_bib0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2007.056556","article-title":"Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics","volume":"45","author":"Antoniou","year":"2008","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.maturitas.2017.06.002_bib0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2350-9-116","article-title":"Selecting a BRCA risk assessment model for use in a familial cancer clinic","volume":"9","author":"Panchal","year":"2008","journal-title":"BMC Med. Genet."},{"issue":"4","key":"10.1016\/j.maturitas.2017.06.002_bib0105","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/bcr2118","article-title":"Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer","volume":"10","author":"Thirthagiri","year":"2008","journal-title":"Breast Cancer Res."},{"issue":"23","key":"10.1016\/j.maturitas.2017.06.002_bib0110","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1001\/jama.297.23.2587","article-title":"Limited family structure and BRCA gene mutation status in single cases of breast cancer","volume":"97","author":"Weitzel","year":"2007","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.maturitas.2017.06.002_bib0115","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2017.06.002_bib0120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s12282-015-0648-1","article-title":"Dissimilarity between sporadic, non-BRCA1\/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population","volume":"23","author":"Riahi","year":"2015","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.maturitas.2017.06.002_bib0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.maturitas.2013.03.002","article-title":"Association of BRCA1\/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age","volume":"5","author":"Tea","year":"2013","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.maturitas.2017.06.002_bib0130","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.breast.2014.08.010","article-title":"Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less","volume":"3","author":"Bayraktar","year":"2014","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.maturitas.2017.06.002_bib0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/humupd\/dmr050","article-title":"Genetics of age at menarche: a systematic review","volume":"18","author":"Dvornyk","year":"2012","journal-title":"Hum. Reprod. Update"},{"issue":"17","key":"10.1016\/j.maturitas.2017.06.002_bib0140","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"83","author":"Boyd","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.maturitas.2017.06.002_bib0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12687-012-0096-y","article-title":"Genetic services and testing in Brazil","volume":"4","author":"Horovitz","year":"2013","journal-title":"J. Commun. Genet."},{"issue":"3","key":"10.1016\/j.maturitas.2017.06.002_bib0150","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1590\/S1415-475738320140204","article-title":"Costs of genetic testing: supporting Brazilian Public Policies for the incorporating of molecular diagnostic technologies","volume":"38","author":"Schlatter","year":"2015","journal-title":"Genet. Mol. Biol."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851221730590X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851221730590X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:09:24Z","timestamp":1759914564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851221730590X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":30,"alternative-id":["S037851221730590X"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.06.002","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictability of BRCA1\/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}